OPTIMIZING LEVETIRACETAM SURFACTANT-BASED NANOVESICLES (LEV-NVS) GEL FOR TREATING EPILEPSY USING EXPERIMENTAL DESIGN

Authors

  • MAHMOUD H. TEAIMA Department of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt https://orcid.org/0000-0002-7565-301X
  • HUSSIEN MOHAMED AHMED EL-MESSIRY Pharmaceutics Department, Egyptian Drug Authority, Cairo, Egypt https://orcid.org/0000-0002-3517-2027
  • HAJAR ABDULRADI SHAKER Pharmaceutics Department, Egyptian Drug Authority, Cairo, Egypt
  • MOHAMED A. EL-NABARAWI Department of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
  • DOAA A. HELAL Department of Pharmaceutics, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt https://orcid.org/0000-0002-1222-8112

DOI:

https://doi.org/10.22159/ijap.2023v15i2.46450

Keywords:

intranasal, Levetiracetam, nanovesicles, brain-targeted, antiepileptic, solvent evaporation technique

Abstract

Objective: To develop and estimate the intranasal delivery of Levetiracetam surfactant-based nanovesicles (Lev-Nvs) as a brain-targeted antiepileptic delivery system prepared via solvent evaporation technique.

Methods: Optimized formulation F (OPT) chosen by the Design-Expert® program gave the highest entrapment efficiency (EE%) was  incorporated into the gel. An experimental design was adopted utilizing various (span 65) surfactants and different cholesterol ratios.The (Lev-Nvs) nanovesicles were formulated by solvent evaporation technique and evaluated for in-vitro characterization parameters such as zeta sizer,Transmission Electron Microscopy (TEM), zeta potential .The nasal gel was evaluated for drug-excipient interactions utilizing Fourier Transform Infrared Spectroscopy (FTIR) and subjected to in-vitro and in-vivo release studies,

Results: The results indicated that the entrapment efficiency (EE%) of Levetiracetam surfactant-based nano-vesicles (Lev-Nvs) could be modulated by the alterations in surfactant and cholesterol concentrations. Optimized formulation F (OPT) showed an entrapment efficiency of (87.9 ± 1.06 %), (206.7 ± 20.43 nm) particle size, (-34.1) zeta potential and (0.979) PDI. The nanovesicle nasal gels of the F(OPT) were prepared using Carbopol 940 at different concentrations. G 0.375 formulation showed the best in vitro drug release (87.36%) after 12 hrs. Finally, the comparative in vivo pharmaco-kinetics release studies on rats revealed considerable, sustained release of the nanovesicle nasal gel and higher relative bioavailability than an equivalent dose of oral solution (293.85%).

Conclusion: Our study proves the improved efficacy of Levetiracetam as a surfactant-based nanovesicle intranasal gel in the brain targeting antiepileptic medication.

Downloads

Download data is not yet available.

References

Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harbor perspectives in medicine. 2015;5(6):a022426.

Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. Pharmacol. Ther. 2010;35(7):392.

Minardi C, Minacapelli R, Valastro P, Vasile F, Pitino S, Pavone P, et al. Epilepsy in children: from diagnosis to treatment with focus on emergency. J. Clin. Med. 2019;8(1):39.

Howard P, Remi J, Remi C, Charlesworth S, Whalley H, Bhatia R, et al. Levetiracetam. J. Pain Symptom Manag. 2018;56(4):645-9.

Brittain HG. Profiles of drug substances, excipients, and related methodology: Academic press; 2020.

Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharmac Sci. 2000;11:1-18.

El-Nabarawy NA, Teaima MH, Helal DA. Assessment of spanlastic vesicles of zolmitriptan for treating migraine in rats. Drug Des. Devel. Ther. 2019;13:3929.

Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther. Deliv. 2014;5(6):709-33.

Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv. Transl. Res. 2013;3(1):42-62.

Illum L. Nasal drug delivery—Recent developments and future prospects. J Control Release (JCR). 2012;161(2):254-63.

Mistry A, Stolnik S, Illum L. Nose-to-brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol. pharm. 2015;12(8):2755-66.

Teaima MH, Yasser M, El-Nabarawi MA, Helal DA. Proniosomal telmisartan tablets: formulation, in vitro evaluation and in vivo comparative pharmacokinetic study in rabbits. Drug Des. Devel. Ther. 2020;14:1319.

Jafarieh O, Md S, Ali M, Baboota S, Sahni J, Kumari B, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 2015;41(10):1674-81.

Abdel-Rashid RS, Helal DA, Omar MM, El Sisi AM. Nanogel loaded with surfactant based nanovesicles for enhanced ocular delivery of acetazolamide. INT J NANOMED. 2019;14:2973.

Abdelmonem R, El Nabarawi M, Attia A. Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. Drug Deliv. 2018;25(1):70-7.

Teaima MH, Abdelhalim SA, El-Nabarawi MA, Attia DA, Helal DA. Non-ionic surfactant based vesicular drug delivery system for topical delivery of caffeine for treatment of cellulite: design, formulation, characterization, histological anti-cellulite activity, and pharmacokinetic evaluation. Drug Dev. Ind. Pharm. 2018;44(1):158-71.

Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288.

Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, Akhoundi Kharanaghi E, Mohammadnejad Arough J, et al. Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A comprehensive review. Int. J. Polym. Mater. 2018;67(6):383-400.

Qumbar M, Imam SS, Ali J, Ahmad J, Ali A. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: in-vitro characterization and in-vivo activity. Biomed. Pharmacother. 2017;93:255-66.

Teaima MH, El Mohamady AM, El-Nabarawi MA, Mohamed AI. Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery. Drug Dev. Ind. Pharm. 2020;46(5):751-61.

Abdelmonem R, Elhabal SF, Abdelmalak NS, El-Nabarawi MA, Teaima MH. Formulation and characterization of acetazolamide/carvedilol niosomal gel for glaucoma treatment: In vitro, and in vivo study. Pharmaceutics. 2021;13(2):221.

Gu F, Ma W, Meng G, Wu C, Wang Y. Preparation and in vivo evaluation of gel-based nasal delivery system for risperidone. Acta Pharm. 2016;66(4):555-62.

Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. Aaps Pharmscitech. 2010;11(3):1119-27.

Hao Y, Zhao F, Li N, Yang Y. Studies on a high encapsulation of colchicine by a niosome system. Int. J. Pharm. 2002;244(1-2):73-80.

Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS pharmscitech. 2008;9(3):740-7.

Ruwizhi N, Aderibigbe BA. The efficacy of cholesterol-based carriers in drug delivery. Molecules. 2020;25(18):4330.

Mathure D, R Madan J, N Gujar K, Tupsamundre A, A Ranpise H, Dua K. Formulation and evaluation of niosomal in situ nasal gel of a serotonin receptor agonist, buspirone hydrochloride for the brain delivery via intranasal route. Pharm. Nanotechnol. 2018;6(1):69-78.

Abdelkader H, Farghaly U, Moharram H. Effects of surfactant type and cholesterol level on niosomes physical properties and in vivo ocular performance using timolol maleate as a model drug. J. Pharm. Investig. 2014;44(5):329-37.

Nie S, Hsiao WW, Pan W, Yang Z. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. int j nanomed. 2011;6:151.

Singh RK, Deora AS. 5-fluorouracil impregnated niosomal-in situ gel (thermo-sensitive) for oral cancer: design, characterization, in vitro/ex vivo evaluation. Int. J. Appl. Pharm. 2022;14(4):126-37. doi: 10.22159/ijap.2022v14i4.44195.

Saraswathi T, Mothilal M. Development of rivastigmine loaded self assembled nanostructures of nonionic surfactants for brain delivery. Int. J. Appl. Pharm. 2021:205-15.

Parvez Baig R, Wais M. Formulation and Development of Proniosomal Gel for Topical Delivery of Amphotericin B. International Journal of Pharmacy and Pharmaceutical Sciences. 2022:37-49. doi: 10.22159/ijpps.2022v14i1.43237.

Akbari J, Saeedi M, Enayatifard R, Morteza-Semnani K, Hashemi SMH, Babaei A, et al. Curcumin Niosomes (curcusomes) as an alternative to conventional vehicles: A potential for efficient dermal delivery. J Drug Deliv Sci Technol. 2020;60:102035.

SP ST, Mothilal M, Damodharan N, Jaison D. Screening and optimization of valacyclovir niosomes by design of experiments. Int. J. Appl. Pharm. 2018:79-85.

Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H. Nasal absorption of metoclopramide from different Carbopol® 981 based formulations: In vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm. 2006;64(2):246-54.

Published

22-12-2022

How to Cite

TEAIMA, M. H., EL-MESSIRY, H. M. A., SHAKER, H. A., EL-NABARAWI, M. A., & HELAL, D. A. (2022). OPTIMIZING LEVETIRACETAM SURFACTANT-BASED NANOVESICLES (LEV-NVS) GEL FOR TREATING EPILEPSY USING EXPERIMENTAL DESIGN. International Journal of Applied Pharmaceutics, 15(2). https://doi.org/10.22159/ijap.2023v15i2.46450

Issue

Section

Original Article(s)

Most read articles by the same author(s)